We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.375 | 2.63% | 14.625 | 656,894 | 10:18:25 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 14.25 | 15.00 | 14.625 | 14.25 | 14.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Business Services, Nec | 2.19M | -20.13M | -0.0624 | -2.34 | 45.98M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:05:44 | O | 10,000 | 14.625 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/7/2024 | 10:08 | UK RNS | Angle PLC Standard form for notification of major holdings |
| 12/7/2024 | 15:38 | UK RNS | Angle PLC Standard form for notification of major holdings |
| 11/7/2024 | 15:07 | UK RNS | Angle PLC Result of 2024 Annual General Meeting |
| 21/6/2024 | 10:52 | ALNC |  IN BRIEF: Angle says open offer raises proceeds of GBP500,000 |
| 21/6/2024 | 07:00 | UK RNS | Angle PLC Result of open offer |
| 18/6/2024 | 14:41 | UK RNS | Angle PLC Posting of 2023 Annual Report & Notice of the AGM |
| 11/6/2024 | 07:00 | UK RNS | Angle PLC Parsortix and assays being showcased at EACR 2024 |
| 06/6/2024 | 16:37 | UK RNS | Angle PLC Publication of Circular |
| 05/6/2024 | 16:32 | ALNC | EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows |
| 05/6/2024 | 16:04 | UK RNS | Angle PLC Results of placing and subscription |
Angle (AGL) Share Charts1 Year Angle Chart |
|
1 Month Angle Chart |
Intraday Angle Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 26/7/2024 | 10:34 | ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY | 25,731 |
| 28/6/2024 | 13:19 | AGL has been Jinxed by the God of Shite. 10p Target | 266 |
| 06/6/2024 | 17:53 | ANGLE PLC THREAD - LIQUID BIOPSY COMPANY GOING TO 0P | 7 |
| 12/2/2024 | 09:42 | Angle PLC | 660 |
| 29/1/2024 | 20:18 | ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE." | 3,756 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 16:05:44 | 14.63 | 10,000 | 1,462.50 | O |
| 2024-07-26 15:29:10 | 14.32 | 34,917 | 5,000.11 | O |
| 2024-07-26 15:28:29 | 14.38 | 34,768 | 5,000.13 | O |
| 2024-07-26 15:25:23 | 14.47 | 10,000 | 1,447.00 | O |
| 2024-07-26 15:16:24 | 14.38 | 34,805 | 5,004.96 | O |
| Top Posts |
|---|
Posted at 25/7/2024 08:47 by bones698 I think there's a growing realisation that the reveine miss is more than likely and that there are very few now saying otherwise says it all. What impact it has on the share price remains to be seen but last time it wasnt very pretty at all. Wethwr they can announce something positive to lift the share price before then is very possible but with them saying only 1 or 2 deals likely before eoy it's not looking great atmI think the last raise was at a very good price in the is market but what s different is it looks like the majority of that money came for the usa so that lessened the damage. Kudos for having that option and seeing the state of uk equity money it's a good job otherwise this would have been in single digits. Wether that continues to be an option one has to hope so or things could get ugly if they have to go to UK equity for money. The business made excellent progress on. Alot of fronts in 2023 and 24 yet the money is slow to grow and deals taking years to get signed. It still comes back to the AZ 6 months trial and will that move onto a bigger deal or not. That could be a huge turning point. If it does that then wil add confidence to other such deals sling the same. If it doesn't then it's a concern. Still wisting for Septembers results for me before I decide |
Posted at 24/7/2024 15:39 by ohwhatfun Investor logic, revenue missed, market reaction.Quite clearly a few agree, revenue highly likely to be missed, news forced and with such re revenue factored in, it forms part of the forecast, 12 months of cash. I was/am a pending investor, waiting for £20m in a raise around mid year, a raise forecast to happen, but trashed by holders. Cash runway, went from Q4 to Q1 to into Q2 2025, and would have included the forecast cash. Burn rate about £1.3m per month. Cash Dec 23 £16.2m. All things being equal and as they were, cash June 23 about £8m £8m would take the cash runway to Q4 as stated, the full revenue into Q1/Q2. Raise of 6 months worth, revenue not hit should mean another raise before year end. It all depends on forecast savings and the monthly cash burn. So holders sit waiting for the hope of that one customer mentioned pre year end and an share price spike. Hovering investors think (because it always happens) that the market will give AGL a kicking on the miss. So news spike, revenue miss, which order. Either way if it went higher, followed by revenue miss, it will probably be this price or lower. Then the dark clouds of a fund raise build, typically a spike to enable forward selling/shorting. So the sit and wait crew see factors where they think the coin flip will land their way, spikes prior are simply unknown unpredictable events. So some go with what they can see, rather than rabbits foot luck. They hope to do one deal this year, not confident on the deal, hope. You can forget possibly 2, no hype type CEOs making likely unachievable forecasts, use hope and possibly in their pump. It was all about avoiding a bigger discounted raise, gambling on deals. Gamble made, we’ll see what happens in the coming months. |
Posted at 23/7/2024 08:33 by ohwhatfun Just read the AGM notes Timbo thanks, and replies.Fund raise. No some were not saying trouble fund raising, they said trouble raising the typical required amount £20m. Previous raises have been £20m with more cash in the bank at the time of the raise. Had they raised £20m, as per posts, various new private investors would have bought, others would add. Instead you have a number of investors doubtful of revenue claims, knowing that event triggers negative news, and the miss shortens the time to the next raise. Why it’s difficult to raise currently at prices and amounts is in the notes. Some mention Avacta 50p raise 75p now, it was over £1 shortly before the raise, with posters trashing others who suggested a big discounted raise was coming. Revenue this year HOPE to get 2 more customers this year, what over £2m each against examples of £150k. Not confident or very confident, HOPE. Oversubscribed raise, show me news of raises where they are not oversubscribed over the years. It’s been explained a number of times, fund raises are supposed to be closed circles but are far from it. In the subscribed list for AGL would have been demand to close short positions opened in knowledge of the raise. Just about every raise sees the share price fall below the raise price, yet AGL seem oblivious to this, suggesting incompetence. The loss of bread and butter small company revenue in this sector is evident in other companies, 75%+ revenue drops in some cases, explained as funding drying up. That’s not AGL that’s the sector. AGLs fix was to proactively start chasing big Pharma. All the confidence and loud claims now seems to be based on 2 with HOPE. Hope based on hard-nosed sale tactics. Yeah the deal is you pay for everything, we keep the IP you create and paid for. I fail to see the buyer carrot on a stick there, minnows trying to bully majors. The hope of 2 more customers, needs to be done swiftly to count for revenue this year. It sounds like revenue is going to be missed by some way. That’s not a good advert for new investors to buy now. Some don’t like coin flip investment timing |
Posted at 18/7/2024 20:20 by bones698 Atm it's hard to see where the required revenues will come from. We all know even adw, that there is the potential for some large deal with AGL nobody denies that but the relaity thius far hasn't shown the big numbers are coming. Even stage 2 with the likes of AZ and eisai are for 1-3 m and they aren't at that stage with them yet. Illumia could be but seems more like a gradual increasing deal selling to their clients so not a fixed deal.Then you have to consider that we are welll past half way in 2024 and the revenues won't them all be added into this year's numbers but mostly rolll over to next year. The value of the contracts spread out over the length of the deal announced. With that said finding over 5m in revenues looks a long shot. I suspect a revenue miss is coming and we all know the impact that could have on the share price here. There's some conflicting signals with dermot increasing his holding and illumia panels being worked on with news on them soon according to AN. There has been a lot of progress made, the deals with AZ are not to be sniffed at and the first one is due end of October so we will see if that translates into a bigger deal as intimated by AN in the presentations. For me the odds are on a revenue miss but there is always the chance of the rabbit out of the hat with AGL. The last revenue miss was by a mere 200k which resulted in a drop from around 40p down to around 15p. For me this might explain why they raised money recently too but also they raised money to avoid a going concern on the accounts. Its all part of the game aim is a big gambling wheel, getting the timing right is always a big part of how well your investments do. For now I'm out and looking for a point to re-enter. The interims aren't too far away in september so I might wait to see what they say in them. |
Posted at 12/7/2024 09:02 by timbo003 See below a few notes from Yesteday's AGM which I think covers the most important topics discussed, I might of missed out a few points, but to keep expeditious I have opted to post it as is.Pharma Services Research suggests that the average success rate of phase II (proof of Concept) clinical trials increases from about 28% to about 46% when a biomarker is involved with patient selection, so there is a lot of interest from Pharmas to use appropriate biomarkers when designing clinical studies. Angle’s strategy is to have the pharma customer pay all development costs if they require a new biomarker assay based on Parsortix. Once developed the assay belongs to Angle and not the Pharma customer. The ideal strategy with a new partner is to go for depth, breadth and Halo (see below) * Depth: once contracted to develop a parsortix assay, Angle look to employ the assay in all stages of clinical development, from Phase I to Phase IV. * Breadth: seek opportunities to develop other Parsortix based assays for other drugs in the Pharma’s oncology portfolio. * Halo: Leverage relationship with (named) Pharma customer to attract new Pharma customers. Currently the emphasis is on protein assays, that is important and you can only do that with intact cells (biopsy or CTCs) – you cannot do this with conventional liquid biopsy (fragments of dead cells). However, protein assay is only the start, the really big opportunity will be when we get into molecular analysis, doing DNA and in particular RNA sequencing – you cannot do RNA analysis on ctDNA from liquid biopsies. Sequencing of cancer cells to look for mutations which have targeted therapy is a very big opportunity. There is a lot of Pharma investment going into that. Eisai The current work focuses analysing CTCs in a small clinical trial using Eisai’s new HER2 ADC drug (£3K per blood sample analysed) , if successful this could lead to further Phase II and Phase III studies. Eisai have stated from the onset of the project that if the clinical program is successful they intend to licence and market the product with a companion diagnostic (i.e. parsortix based HER2 analysis on CTCs). This could ultimately lead to recurring revenues of between £20m and £100m/year to Angle. Astra Zeneca Two projects with AZ * Parsortix based DDR (DNA Damage Response) assay. DDR inhibitors are a new class of oncology drugs being investigated by numerous Pharmas including AZ * Parsortix based Androgen Receptor assay Discussions with AZ had been taking place over a number of years, contract agreed in broad terms, at the last minute AZ threw a curved ball and requested that the contract was arranged through Scientist.com, Scientist.com conducted extensive due diligence on Angle on behalf of AZ, however when it came to finalising the contract the terms and conditions were unacceptable to Angle, these stated that AZ would own the assay, this was unacceptable and Angle refused to sign, Scientist.com went back to AZ and came back with a new contract where Angle would own the assay with AZ bearing all costs for the development. Scientist.com have many large Pharma clients (see www.scientist.com), and now Angle is on their books as an approved supplier which bodes well for the future. In addition to Eisai and AZ there are ongoing contracts/collaborat Angle are also currently in discussions with 11 pharma / biotech customers (6 of them are house hold names) and hope to add one or possibly two of these to the list of customers this year, the plan is to get about 20 such customers signed up. Recent Placing and open offer: The fund raising environment at the time when fund raising discussions were taking place were fairly grim and share prices in the sector depressed. Many OEIC funds have been forced to make redemptions depressing share prices of their underlying investments and the amount of available funds available for OEICs to invest. For this round some institutional investors who would normally have participated in the funding roadshow didn’t want to cross the wall to be taken inside. Yet despite this situation the placing was oversubscribed whilst offering a relatively small discount. Many existing holders participated in the funding round (the placing or open offer), 35% (approx.) of the funds were raised from US investors. The Angle BOD were pleased with the (small) discount achieved with the placing, but disappointed at the market’s reaction to the announcement with the share price trading below the placing price which meant a low uptake with the open offer. One shareholder made the point that if Angle had made it clear in the RNS announcements (and the open offer document) that the placing was oversubscribed, it would probably have resulted in a better market reaction and a greater demand in the open offer (Good point I thought), Ian said they had never commented on this in previous announcements (but they don’t normally have open offers to accompany placings do they?). A couple of shareholders stated that they ducked the open offer as they didn’t want to pay 15p when they could buy in the market at 14p or thereabouts. I offered the suggestion of including a few out of the money warrants with the new shares, but Andrew said they had wanted to to keep the fund raise as Vanilla as possible. CellKeep There was a question on CellKeep. Andrew managed to produce one from his brief case which he showed us. It sounds like there has been potential interest in commercialisation, although it might require modifications for other applications (such as for CF) where the volume of fluid may be greater or smaller than the volume used for Parsortix samples (0.2ml) and I got the impression that this was not a top priority Product Business Selling Parsortix, consumables and (Portrait) assays to Hospitals and Universities remains a very important part of the overall commercial strategy as it provides additional incentive for pharma to adopt a companion diagnostic approach for their new drug developments, having an assay method close to hand at the hospital/near the patients makes going down the companion diagnostic route a more obvious choice for Pharma partners. |
Posted at 18/6/2024 14:26 by kryptonsnake The share price isn't falling fast enough so all the idiots are turning up todayIgnore the noise. The share price will recover and then some It's just a matter of time before more contracts are signed sent from my iPhone |
Posted at 05/6/2024 07:49 by miavoce Usual behaviour is that the share price will drop to the offer price as soon as the market opens. This is certainly what I am expecting. If this occurs there will be no forward short selling as that only occurs before the share price has dropped to the offer price. |
Posted at 23/5/2024 07:21 by adw198 Placing coming here soon as the cash is running low. Some decent news on deals hoping to lift the share price prior to it but it'doesnt seem to be working and the share price falling back quickly. Depending when it comes likely to be another painful one for shareholders.A shame as they seem to be getting there just not quite fast enough and that might cost pis here as the market is awful to raise in. Those that have left it late to raise money have been hammered, see Gdr sce, Polx of how tough it might get here. A shame as I think this out of most of them has a good product and future but not before one mo ——— And before you start giving me the thumbs down just reflect they aren’t my words but infact what the rat bones698 was saying on another share yday. He’s obviously short there so that kind of analysis is fine for him to make. What a lair and a hypocrite - don’t fall for it. |
Posted at 12/5/2024 23:19 by liberatingsteptoe today's DTel Questor: I can think of one Co they might be interested in...... Absolutely no information but it does make one think...... Just hope that things here progress for a while yet and that LTH get their just rewards.Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq. The move – Abcam had made Aim its home since 2005 and was one of its biggest companies – was seen at the time as a blow to the Government’s efforts to champion the UK’s most innovative companies. It was also an indication that the entire London listings market was in decline with many companies since being bought out by predators and seeking higher valuations overseas. Abcam now has a new owner. Since late last year, the company has been part of Danaher Corporation, the New York-listed life sciences and diagnostics giant. Danaher paid $5.7bn (£4.6bn) in cash for Abcam, which makes and sells products, including proteins and reagents, used in medical research. It has added the business to its already extensive array of medical products and services, which range from cell production and new drugs discovery to the instruments used in clinical testing. In its former guise, Abcam had a devoted following among individual UK shareholders. Danaher has a fanbase of its own too: the world’s best fund managers. Nine of them hold the stock, and each one is among the top 3pc of the 10,000 equity fund managers tracked by financial publisher Citywire. This smart-money backing has led to Danaher being AAA rated by Citywire Elite Companies, which rates companies based on their popularity with the world’s best-performing fund managers. Danaher share price Line chart with 1274 data points. $ per share View as data table, Danaher share price The chart has 1 X axis displaying Time. Data ranges from 2019-04-22 00:00:00 to 2024-05-10 00:00:00. The chart has 1 Y axis displaying $. Data ranges from 107.5989 to 294.6626. $ 2020 2021 2022 2023 2024 50 100 150 200 250 300 SOURCE: BLOOMBERG Danaher share price $ per share End of interactive chart. While Abcam is not transformational for Danaher – it represents just 2.5pc of overall revenue – top fund manager Neal Kaufman, who holds Danaher shares in the Baron Health Care Fund, says the deal underlines a key attribute: “This acquisition is reflective of Danaher’s thoughtful approach to acquisitions, through which the company has been able to add best-in-class assets in attractive end markets like bioprocessing and proteomics [the study of sets of proteins].” Management, which has acquired hundreds of businesses since Danaher was created in 1984, is aiming to grow Abcam’s revenues by the high-single-digit percentages over the long term. This is in line with the wider group’s core growth target. It’s an impressive aim for a company of its scale which last year reported revenues just shy of $24bn. Danaher’s management team is also happy to reshape the group’s portfolio of businesses with disposals. Last year, for example, it spun off its environmental services arm Veralto to create a separately listed business now worth $24bn. It did the same with its $3.5bn dental operation, Envista, in 2019. In both cases, Danaher’s shareholders benefited, and it would be no surprise to see the company do something similar again. There is plenty enticing Kaufman and the other leading fund managers backing the company beyond its savvy deals. Among these attractions is Danaher’s wide spread of products, high degree of recurring revenues and those punchy core growth targets already mentioned. Across the company’s three business lines – of biotechnology, life sciences and diagnostics – around 80pc of revenue is recurring. This provides a striking degree of certainty in a sector where earnings can be volatile. Danaher’s expertise in areas such as biologics, or medicines made using living cells or organisms, puts it at the cutting edge of new treatments for diseases such as cancer and autoimmune deficiencies. Growth should also benefit from rising demand for rapid diagnostics. It’s not all plain sailing. Many smaller biotechs have been caught up in a funding crunch for the past two years and the group has lost orders as a result. The good news is that Danaher said earlier this month it had noticed an improvement, though this has yet to translate into an increase in orders. Revenues also fell last year, and will again this year, as the effects of a Covid-related sales boost fade and customers finish running down excess stock. Danaher is confident the lull will be short-lived and is sticking with its central growth targets. The wider market also appears optimistic based on the punchy rating attached to the shares of 32 times forecast earnings. That’s a price several of the world’s best professional investors think is worth paying. This column agrees. Questor says: buy Ticker: NYSE:DHR Share price: $253.38 Read the latest Questor column on telegraph.co.uk every Sunday, Tuesday, Wednesday, Thursday and Friday from 5am. Read Questor’s rules of investment before you follow our tips. |
Posted at 11/5/2024 08:22 by adw198 @hoohah In November they guided the market they expected to triple revenue to £6m. Based on that massive growth projection they forecast cash lasting till Q2 25.Some of us are concerned whether we’re on track to achieve £6m because there’s no evidence to suggest that. We’ve had a $250k deal, a £150k deal and the £500k deal with AZ that complete Q1 25. Fair enough we don’t what else is being achieved that they haven’t announced and that’s particularly true of product sales but at the very least it’s a risk. If they aren’t on track and need to guide the market the results will be the time to do it. Those results are strangely later than previous which might suggest a placing will be announced around the same time. A placing isn’t the end of the world and I personally will almost certainly buy back in after it arrives because for me it de risks the prospects here. But it would most likely lead to a drop in the share price Bones knows this very well because it’s the kind of analysis he applies to some of the many other message boards he slates other shares on. He just happens to want to pump the price here which is why he’s so aggressive to anyone who doesn’t play along with his agenda. What he’s admitted is he sold in January the exact time he was posting regularly about how great things were. Yet he’s also announced he hasn’t sold a penny. Even if the above results / placing does play out it’s also possible there could be a stonking deal announced any time to send the share price much higher. That’s fine with me, we also have to make our own decisions and live with the consequences. I watched RENE go to nothing from a similar position so just want to manage my risk. Results will be in the next 2 weeks so the good news is we’ll be finding out very soon. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
